Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; and strategic collaboration with Ascidian Therapeutics for discovery and development of therapies for undisclosed monogenic kidney diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

• 5d agoPOSITIVE
  American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades'

  CNBC's Halftime Report has identified Eli Lilly and Company as a top pick, signaling strong investor confidence. The pharmaceutical giant's inclusion in 'Final Trades' suggests positive momentum and potential for future growth. While specific financial data is not detailed, expert recommendations often precede significant market movements. Investors are advised to monitor Lilly's performance closely, as this endorsement could translate into increased buying pressure and a potential upward trend in its stock price.

• 8d agoPOSITIVE
  Lilly's Weight Loss Sets High Bar for Obesity Drug Race

  Eli Lilly and Company's advancements in the GLP-1 market for obesity drugs are setting a high benchmark for competitors, according to Sam Fazeli, Senior Pharmaceuticals Analyst at Bloomberg Intelligence. The company's progress in this rapidly growing sector suggests strong future revenue potential and market leadership. Investors are closely watching Lilly's pipeline and clinical trial results, as success in obesity treatments could significantly boost its valuation and market share, potentially outperforming rivals and driving substantial shareholder returns.

• 9d agoPOSITIVE
  Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages

  Eli Lilly and Company announced positive results for its weight-loss drug, tirzepatide (Foundayo), demonstrating significant efficacy across various menopausal stages. Studies showed up to a 14.4% reduction in body weight at 72 weeks. This development is crucial as it addresses a specific demographic often facing challenges with weight management due to hormonal changes. The findings suggest a strong potential for tirzepatide in a key patient group, which could lead to expanded market share and increased demand for the drug, positively impacting Eli Lilly's revenue and stock performance.

• 12d agoPOSITIVE
  Here's How Much $1000 Invested In Eli Lilly 5 Years Ago Would Be Worth Today

  An investment of $1000 in Eli Lilly and Company five years ago would have grown to approximately $6,800 today, representing a substantial 580% return. This impressive performance is largely attributed to the company's strong pipeline and successful launches of blockbuster drugs, particularly in the diabetes and obesity treatment space with Zepbound and Mounjaro. The sustained demand and positive clinical trial data have fueled significant stock appreciation, far outpacing the broader market. For investors, Eli Lilly's consistent innovation and market leadership in high-growth therapeutic areas underscore its potential for continued long-term value creation.

• 20d agoPOSITIVE
  Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

  Eli Lilly's GLP-1 medications, including the pill Foundayo and injection Zepbound, are set to be covered by CVS. This development is expected to significantly broaden access for millions of Americans, potentially boosting sales and market share for Lilly's weight-loss and diabetes treatments. The expanded coverage by a major pharmacy benefit manager like CVS signals growing acceptance and integration of these innovative therapies into mainstream healthcare, which could lead to increased revenue streams and further solidify Lilly's leadership in the GLP-1 market.

• 21d agoPOSITIVE
  Lilly Goes on $20B Buying Spree as It Seeks Next Act

  Eli Lilly and Company has embarked on an aggressive acquisition strategy, announcing deals valued at over $20 billion in 2026. This significant spending spree indicates the pharmaceutical giant's intent to diversify its portfolio beyond its highly successful obesity drug franchise. The move signals a proactive approach to securing future growth drivers and expanding its therapeutic reach, which could lead to new revenue streams and market opportunities. Investors may view this as a strategic move to bolster long-term value and innovation.

• 22d agoPOSITIVE
  Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion

  Eli Lilly and Company is set to acquire three clinical-stage vaccine developers for up to $3.8 billion, signaling a strategic expansion beyond its obesity drug success into infectious diseases. The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company grant Lilly access to innovative technologies and experimental immunizations targeting shingles, common bacterial pathogens, and the Epstein-Barr virus. This move underscores Lilly's commitment to disease prevention and diversification, potentially positioning it as a significant player in the vaccine market. Investors may view this as a positive step towards broadening Lilly's revenue streams and long-term growth prospects.